Current Knowledge About Aprocitentan in Hypertension.
Authors: Bank-Mikkelsen EM, Grimm D, Wehland M. DOI: 10.3390/ijms262311431 Abstract Summary Aprocitentan, a novel dual endothelin receptor antagonist, shows promise for treating resistant hypertension. Studies reveal significant blood pressure reductions within 14 days at...
Read moreDetails




